alk genetic mutations that are studied in lung adenocarcinoma
Age was categorized in three groups in this study, and a higher EML4-ALK fusion gene mutation rate (24%) was observed in the youngest age group, of 20–40 years (P=0.006), as compared to 3.9% and 1.9% in the age groups of 40–60 years and >60 years, respectively. In an East Asian population, the EML4-ALK fusion gene positivity was found to be 5%, mostly in young patients who were never-smokers. However, a higher incidence of ALK mutations was reported in Chinese NSCLC patients, particularly in those with adenocarcinoma lacking EGFR/K-RAS mutation. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. 1  Abstract. 2  Fulltext. 3  Metrics. 4  Get Permission. To date, there is only one published report from India on EML4 ALK mutations demonstrating a positivity of 2.7%. 16 Our study confirms that EML4-ALK gene fusions are present in lung adenocarcinomas from Indian patients, and the 3% incidence of EML4-ALK gene fusion in EGFR mutation-negative cases is similar to what has been observed in other Western and Asian populations. 40–42 In the present study, a higher EML4-ALK fusion gene mutation rate was observed in females than in males (9.5% ... Background. 1  Pulmonary adenoid cystic carcinoma (PACC) is an uncommon neoplasm of the lung but represents the predominant type of salivary gland-type lung carcinoma. 2  We reviewed 24 cases of primary PACC between 2000 and 2014, including 21 cases reported in our previous study and three new cases added in 2014. The present study was carried out to detect the prevalence of EGFR mutations and EML4-ALK fusions in EGFR mutation-negative cases of NSCLC (adenocarcinoma) as well as to evaluate the clinical characteristics of EGFR mutations and EML4-ALK fusions in EGFR mutation-negative cases of NSCLC. Introduction. 1  Lung cancer is one of the leading causes of cancer-related death in many parts of the world, including India. The overall 5-year survival rate remains at 15% despite significant improvements in the detection and treatment of lung cancer. Background: Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a common feature observed in lung adenocarcinoma. A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in a subset of non-small-cell lung cancer (NSCLC) tumors. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung DC Doval,1 K Prabhash,2 S Patil,3 H Chaturvedi,4 C Goswami,5 AK Vaid,6 S Desai,2 S Dutt,7 VH Veldore,8 N Jambhekar,2 A Mehta,1 D Hazarika,8 S Azam,1 S Gawande,9 S Gupta10 1Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 2Tata Memorial Hospital, Mumbai, 3Bangalore Institute of Oncology, HCG Group, Bengaluru, 4Max Super Speciality Hospital, New ... ALK gene rearrangement in the lung adenocarcinomas is the second most common (1.6-11.7% of NSCLC) targetable genomic change after EGFR mutations. However, the prevalence and clinicopathological features of ALK-rearranged lung adenocarcinomas from North India are lacking. A total of 240 cases of lung adenocarcinoma were screened for EGFR mutations and for ALK expression. Smoking status, TNM stage, and treatment response were recorded in all cases. Out of 240 cases screened, 37 cases were positive for EGFR mutations and 17 cases (7.08%) showed ALK positivity with immunohistochemistry and break-apart FISH.
EML4-ALK is genetic mutations that are studied in lung adenocarcinoma.